Q1 2022 Results

Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Ophthalmology Respiratory & Allergy Oncology: Solid Tumors iscalimab - CD40 inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT04541589 TWINSS Extn (CFZ533B2201E1) Sjögren's syndrome Phase 2 Incidence of Treatment-emergent AES (TEAEs) Change in laboratory evaluations for hematology from baseline to each study visit Change in laboratory evaluations for serum chemistry from baseline to each study visit Change in vital sign measurements from baseline for each post-baseline visit Arm 1 Iscalimab Dose 1 s.c. Q2W Arm 2 Iscalimab Dose 2 s.c. Q2W and Placebo Patients with Sjögren's Syndrome, who participated in the TWINSS core study, CCFZ533B2201(NCT03905525) Primary completion date: 2024 65 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine

View entire presentation